Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106

STAR: ultrafast universal RNA-seq aligner

Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709

clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters

Yu, G., Wang, L.-G., Han, Y., & He, Q.-Y. (2012) · OMICS: A Journal of Integrative Biology · doi:10.1089/omi.2011.0118 · Cited by 36,259

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320

Robust enumeration of cell subsets from tissue expression profiles

Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Inferring tumour purity and stromal and immune cell admixture from expression data

Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778

Signatures of mutational processes in human cancer

Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377

Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma

Armand, P. A., Janssens, A. M., Gritti, G., Radford, J. A., Timmerman, J. M., Pinto, A., Mercadal, S., Johnson, P., Cunningham, D., Leonard, J. P., et al. (2020) · Blood · doi:10.1182/blood.2019004753 · Cited by 95

Mitochondrial DNA mutations drive aerobic glycolysis to enhance checkpoint blockade response in melanoma

Mahmood, M., Liu, E. M., Shergold, A. L., Tolla, E., Tait-Mulder, J., Uribe, A. H., Shokry, E., Young, A. L., Lilla, S., Kim, M., et al. (2024) · Nature Cancer · doi:10.1038/s43018-023-00721-w · Cited by 101

Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy

Vitale, I., Sistigu, A., Manic, G., Rudqvist, N.-P., Trajanoski, Z., & Galluzzi, L. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.01.003 · Cited by 95

Genome-scale screens identify factors regulating tumor cell responses to natural killer cells

Sheffer, M., Lowry, E., Beelen, N. A., Borah, M., Amara, S. N.-A., Mader, C. C., Roth, J. A., Tsherniak, A., Freeman, S. S., Dashevsky, O., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00889-w · Cited by 96

Identification of a neo-epitope dominating endogenous CD8 T cell responses to MC-38 colorectal cancer

Hos, B. J., Camps, M. G. M., van den Bulk, J., Tondini, E., van den Ende, T. C., Ruano, D., Franken, K. L. M. C., Janssen, G. M. C., de Ru, A. H., Filippov, D. V., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1673125 · Cited by 95

Cytotoxic CD8+ Lymphocytes in the Tumor Microenvironment

Iwahori, K. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-35723-8_4 · Cited by 102

Multi-omics analysis: Paving the path toward achieving precision medicine in cancer treatment and immuno-oncology

Raufaste-Cazavieille, V., Santiago, R., & Droit, A. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.962743 · Cited by 101

Cross-talk between cuproptosis and ferroptosis regulators defines the tumor microenvironment for the prediction of prognosis and therapies in lung adenocarcinoma

Shen, Y., Li, D., Qiong, L., Yang, M., Pan, Y., & Li, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1029092 · Cited by 94

The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals

Philips, E. A., García‐España, A., Tocheva, A. S., Ahearn, I. M., Adam, K. R., Pan, R., Mor, A., & Kong, X. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ac119.011747 · Cited by 98

Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies

Walsh, R. J., & Soo, R. A. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920937902 · Cited by 93

Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response

Sato, Y., Fu, Y., Liu, H., Lee, M. Y., & Shaw, M. H. (2021) · BMC Cancer · doi:10.1186/s12885-021-08974-3 · Cited by 100

Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade

Spurr, L. F., Martinez, C. A., Kang, W., Chen, M., Zha, Y., Hseu, R. D., Gutiontov, S. I., Turchan, W. T., Lynch, C. M., Pointer, K. B., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00467-x · Cited by 96

Neutrophils Extracellular Traps Inhibition Improves PD-1 Blockade Immunotherapy in Colorectal Cancer

Zhang, H., Wang, Y., Onuma, A. E., He, J., Wang, H., Xia, Y., Lal, R., Cheng, X., Kasumova, G. G., Hu, Z., et al. (2021) · Cancers · doi:10.3390/cancers13215333 · Cited by 94

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups, Bedognetti, D., Ceccarelli, M., Galluzzi, L., Lu, R. O., Palucka, K., Samayoa, J. A., Spranger, S., Warren, S. E., Wong, K., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0602-4 · Cited by 90

Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors

Pender, A., Titmuss, E., Pleasance, E., Fan, K. Y., Pearson, H., Brown, S. D., Grisdale, C. J., Topham, J. T., Shen, Y., Bonakdar, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1163 · Cited by 87

Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors

Márquez‐Rodas, I., Longo, F., Rodriguez-Ruiz, M. E., Calles, A., Ponce, S., Jové, M., Rubio‐Viqueira, B., Perez‐Gracia, J. L., Gómez‐Rueda, A., López‐Tarruella, S., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb0391 · Cited by 93

Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses

Kidman, J., Principe, N., Watson, M. W., Lassmann, T., Holt, R. A., Nowak, A. K., Lesterhuis, W. J., Lake, R., & Chee, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.587014 · Cited by 94

Base editing screens map mutations affecting interferon-γ signaling in cancer

Coelho, M. A., Cooper, S., Strauß, M. E., Karakoç, E., Bhosle, S. G., Gonçalves, E., Picco, G., Burgold, T., Cattaneo, C. M., Veninga, V., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2022.12.009 · Cited by 94

Breast Cancer Vaccines: Disappointing or Promising?

Zhu, S., & Yu, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.828386 · Cited by 96

PD-1- CD45RA+ effector-memory CD8 T cells and CXCL10+ macrophages are associated with response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma

Cappuyns, S., Philips, G., Vandecaveye, V., Boeckx, B., Schepers, R., Brussel, T. V., Arijs, I., Mechels, A., Bassez, A., Lodi, F., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43381-1 · Cited by 97

Expression of the Circadian Clock Gene BMAL1 Positively Correlates With Antitumor Immunity and Patient Survival in Metastatic Melanoma

de Assis, L. V. M., Kinker, G. S., Moraes, M. N., Markus, R. P., Fernandes, P. A. C. M., & Castrucci, A. M. D. L. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00185 · Cited by 91

The Resistance Mechanisms of Lung Cancer Immunotherapy

Wang, F., Wang, S., & Zhou, Q. H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.568059 · Cited by 90

Systematic dissection of tumor-normal single-cell ecosystems across a thousand tumors of 30 cancer types

Kang, J., Lee, J. H., Cha, H., An, J., Kwon, J., Lee, S., Kim, S., Baykan, M. Y., Kim, S. Y., An, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48310-4 · Cited by 90

Exploiting temporal aspects of cancer immunotherapy

Zemek, R. M., Anagnostou, V., da Silva, I. P., Long, G. V., & Lesterhuis, W. J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00699-2 · Cited by 96

Roles of Neutrophils in Glioma and Brain Metastases

Lin, Y.-J., Wei, K., Chen, P., Lim, M. K., & Hwang, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.701383 · Cited by 88

Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade

Peranzoni, E., Ingangi, V., Masetto, E., Pinton, L., & Marigo, I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01590 · Cited by 85

Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity

Hou, Y., Liang, H. L., Yu, X., Liu, Z., Cao, X., Rao, E., Huang, X., Wang, L., Li, L., Bugno, J., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb0130 · Cited by 85

Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer

Guo, Z., Yuan, Y., Chen, C., Lin, J., Ma, Q., Liu, G., Gao, Y. L., Huang, Y., Chen, L., Chen, L., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00279-3 · Cited by 86

NK cells with tissue-resident traits shape response to immunotherapy by inducing adaptive antitumor immunity

Kirchhammer, N., Trefny, M. P., Natoli, M., Brücher, D., Smith, S. N., Werner, F., Koch, V., Schreiner, D., Bartoszek, E. M., Buchi, M., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm9043 · Cited by 86

Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma

Campbell, K. M., Amouzgar, M., Pfeiffer, S. M., Howes, T. R., Medina, E., Travers, M., Steiner, G., Weber, J. S., Wolchok, J. D., Larkin, J., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.03.010 · Cited by 90

Clinical relevance of PD-L1 expression and CD8 T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer

Liu, S.-Y., Dong, Z.-Y., Wu, S.-P., Xie, Z., Yan, L.-X., Li, Y.-F., Yan, H.-H., Su, J., Yang, J.-J., Zhou, Q., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.09.010 · Cited by 85

Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer

Liu, S., Matsuzaki, J., Wei, L., Tsuji, T., Battaglia, S., Hu, Q., Cortes, E., Wong, L.-P., Yan, L., Long, M. D., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0629-6 · Cited by 85

Tumor immunological phenotype signature-based high-throughput screening for the discovery of combination immunotherapy compounds

Wang, H., Li, S., Wang, Q., Jin, Z., Shao, W., Gao, Y., Li, L., Lin, K., Zhu, L., Wang, H., et al. (2021) · Science Advances · doi:10.1126/sciadv.abd7851 · Cited by 86

Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment

Nguyen, T.-T., Ramsay, L., Ahanfeshar-Adams, M., Lajoie, M., Schadendorf, D., Alain, T., & Watson, I. R. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3365 · Cited by 87

Novel post-translational modification learning signature reveals B4GALT2 as an immune exclusion regulator in lung adenocarcinoma

Zhang, Z., Wang, D., Zhou, G., Jiang, S., Zhang, G., Zhang, L., & Zhang, Z. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010787 · Cited by 85

Reprograming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma

Deng, C., Xu, Y., Fu, J., Zhu, X., Chen, H., Xu, H., Wang, G., Song, Y., Song, G., Lu, J., et al. (2020) · Cancer Science · doi:10.1111/cas.14398 · Cited by 82

Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity

Ma, X., Riaz, N., Samstein, R. M., Lee, M., Makarov, V., Valero, C., Chowell, D., Kuo, F., Hoen, D. R., Fitzgerald, C. W. R., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01108-w · Cited by 87

Leveraging big data of immune checkpoint blockade response identifies novel potential targets

Barèche, Y., Kelly, D., Aghababazadeh, F. A., Nakano, M., Esfahani, P. N., Tkachuk, D., Mohammad, H., Samstein, R. M., Lee, C., Morris, L. G. T., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.08.084 · Cited by 85

Pan‐Cancer Single‐Cell and Spatial‐Resolved Profiling Reveals the Immunosuppressive Role of APOE+ Macrophages in Immune Checkpoint Inhibitor Therapy

Liu, C., Xie, J., Lin, B., Tian, W., Wu, Y., Shan, X., Hong, L., Li, X., Liu, L., Jin, Y., et al. (2024) · Advanced Science · doi:10.1002/advs.202401061 · Cited by 89

Leveraging mitochondrial-programmed cell death dynamics to enhance prognostic accuracy and immunotherapy efficacy in lung adenocarcinoma

Zhang, L., Cui, Y., Zhou, G., Zhang, Z., & Zhang, Z. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010008 · Cited by 84

Efficacy and Outcome of Tofacitinib in Immune checkpoint Inhibitor Colitis

Bishu, S., Melia, J., Sharfman, W. H., Lao, C. D., Fecher, L. A., & Higgins, P. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.10.029 · Cited by 83

Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma

Anagnostou, V., Bruhm, D. C., Niknafs, N., White, J. R., Shao, X. M., Sidhom, J.-W., Stein, J. E., Tsai, H., Wang, H., Belcaid, Z., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100139 · Cited by 87

Systematic characterization of mutations altering protein degradation in human cancers

Tokheim, C. J., Wang, X., Timms, R. T., Zhang, B., Mena, E. L., Wang, B., Chen, C., Ge, J., Chu, J., Zhang, W., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.01.020 · Cited by 85

Machine learning-based tumor-infiltrating immune cell-associated lncRNAs for predicting prognosis and immunotherapy response in patients with glioblastoma

Zhang, H., Zhang, N., Wu, W., Zhou, R., Li, S., Wang, Z., Dai, Z., Zhang, L., Liu, Z., Zhang, J., et al. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac386 · Cited by 82

Molecular patterns of resistance to immune checkpoint blockade in melanoma

Lauss, M., Phung, B., Borch, T. H., Harbst, K., Kaminska, K. K., Ebbesson, A., Hedenfalk, I. A., Yuan, J., Nielsen, K., Ingvar, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47425-y · Cited by 90

Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response

Xiao, Q., Nobre, A., Piñeiro, P., Berciano‐Guerrero, M., Alba, E., Cobo, M., Lauschke, V. M., & Barragán, I. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010286 · Cited by 82

Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes

Wu, W., Liu, Y., Zeng, S., Han, Y., & Shen, H. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01166-3 · Cited by 83

Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma

Esteban-Fabró, R., Willoughby, C. E., Piqué‐Gili, M., Montironi, C., Abril‐Fornaguera, J., Peix, J., Torrens, L., Mesropian, A., Balaseviciute, U., Miró‐Mur, F., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2517 · Cited by 83

Radiation induces dynamic changes to the T cell repertoire in renal cell carcinoma patients

Chow, J. L., Hoffend, N. C., Abrams, S. I., Schwaab, T., Singh, A. K., & Muhitch, J. B. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2001933117 · Cited by 82

Lack of detectable neoantigen depletion signals in the untreated cancer genome

den Eynden, J. V., Jiménez-Sánchez, A., Miller, M. L., & Larsson, E. (2019) · Nature Genetics · doi:10.1038/s41588-019-0532-6 · Cited by 81

A four-DNA methylation biomarker is a superior predictor of survival of patients with cutaneous melanoma

Guo, W., Zhu, L., Zhu, R., Chen, Q., Wang, Q., & Chen, J. (2019) · eLife · doi:10.7554/elife.44310 · Cited by 81

The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis

Wang, C., Qiao, W., Jiang, Y., Zhu, M., Shao, J., Wang, T., Liu, D., & Li, W. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29371 · Cited by 83

Inhibition of UBA6 by inosine augments tumour immunogenicity and responses

(2022) · doi:10.1038/s41467-022-33116-z · Cited by 82

Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies

Zhou, B., Gao, Y., Zhang, P., & Chu, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.693609 · Cited by 81

The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis

Ning, B., Liu, Y., Wang, M., Li, Y., Xu, T., & Wei, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.748674 · Cited by 83

T-cell repertoire diversity: friend or foe for protective antitumor response?

Porciello, N., Franzese, O., D’Ambrosio, L., Palermo, B., & Nisticò, P. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02566-0 · Cited by 88

Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives

Liu, Z., Zhu, Y., Xie, H., & Zou, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1077468 · Cited by 84

Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity

Hao, D., Liu, J., Chen, M., Li, J., Wang, L., Li, X., Zhao, Q., & Di, L. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3862 · Cited by 77

Immunotherapy for advanced thyroid cancers — rationale, current advances and future strategies

French, J. D. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0398-9 · Cited by 80

PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy

Simon, S., Voillet, V., Vignard, V., Wu, Z., Dabrowski, C., Jouand, N., Beauvais, T., Khammari, A., Braudeau, C., Josien, R., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001631 · Cited by 79

Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling

Yofe, I., Landsberger, T., Yalin, A., Solomon, I., Costoya, C., Demane, D. F., Shah, M., David, E., Borenstein, C., Barboy, O., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00447-1 · Cited by 79

The future of affordable cancer immunotherapy

Schaft, N., Dörrie, J., Schuler, G., Schuler‐Thurner, B., Sallam, H., Klein, S., Eisenberg, G., Frankenburg, S., Lotem, M., & Khatib, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1248867 · Cited by 81

Multi-Omics Profiling of the Tumor Microenvironment: Paving the Way to Precision Immuno-Oncology

Finotello, F., & Eduati, F. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00430 · Cited by 77

Comprehensive analysis of the tumor immune micro-environment in non-small cell lung cancer for efficacy of checkpoint inhibitor

Seo, J., Kim, A., Shin, J.-Y., & Kim, Y. T. (2018) · Scientific Reports · doi:10.1038/s41598-018-32855-8 · Cited by 75

Immune selection determines tumor antigenicity and influences response to checkpoint inhibitors

Zapata, L., Caravagna, G., Williams, M. J., Lakatos, E., AbdulJabbar, K., Werner, B., Chowell, D., James, C. T., Gourmet, L. E., Milite, S., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01313-1 · Cited by 75

Complex interplay between tumor microenvironment and cancer therapy

Shen, M., & Kang, Y. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0663-7 · Cited by 76

Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade

Sehgal, K., Portell, A. J., Ivanova, E. V., Lizotte, P. H., Mahadevan, N. R., Greene, J. R., Vajdi, A., Gurjao, C., Teceno, T. J., Taus, L. J., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci135038 · Cited by 78

Melanoma dedifferentiation induced by IFN-γ epigenetic remodeling in response to anti–PD-1 therapy

Kim, Y. J., Sheu, K. M., Tsoi, J., Abril-Rodríguez, G., Medina, E., Grasso, C. S., Torrejon, D. Y., Champhekar, A. S., Litchfield, K., Swanton, C., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145859 · Cited by 79

Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation

Yang, H., Yao, Z., Zhou, X., Zhang, W., Zhang, X., & Zhang, F. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108377 · Cited by 77

Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis

Kato, S., Weng, Q. Y., Insco, M. L., Chen, K. Y., Muralidhar, S., Poźniak, J., Diaz, J. M. S., Drier, Y., Nguyen, N. T., Lo, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0532 · Cited by 75

A pan-cancer transcriptome analysis of exitron splicing identifies novel cancer driver genes and neoepitopes

Wang, T.-Y., Liu, Q., Ren, Y., Alam, S. K., Wang, L., Zhu, Z., Hoeppner, L. H., Dehm, S. M., Cao, Q., & Yang, R. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.03.028 · Cited by 77

Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer

Pereira, B., Chen, C. T., Goyal, L., Walmsley, C. S., Pinto, C. J., Baiev, I., Allen, R., Henderson, L. E., Saha, S. K., Reyes, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23394-4 · Cited by 78

Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8 + T cell clone size and cytotoxicity

Watson, R. A., Tong, O., Cooper, R. A., Taylor, C. A., Sharma, P. K., Aires, A. V. D. L., Mahé, E. A., Ruffieux, H., Nassiri, I., Middleton, M. R., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abj8825 · Cited by 76

Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association

Wu, C.-C., Wang, Y., Livingston, J. A., Zhang, J., & Futreal, P. A. (2022) · Nature Communications · doi:10.1038/s41467-021-27651-4 · Cited by 80

Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response

Stein, J. E., Soni, A., Danilova, L., Cottrell, T. R., Gajewski, T. F., Hodi, F. S., Bhatia, S., Urba, W. J., Sharfman, W. H., Wind‐Rotolo, M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz019 · Cited by 73

Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy

Le, Q., Colevas, A. D., O’Sullivan, B., Lee, A. W. M., Lee, N. Y., Ma, B. B. Y., Siu, L. L., Waldron, J. N., Lim, C. M., Riaz, N., et al. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz044 · Cited by 76

Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges

McKean, W. B., Moser, J. C., Rimm, D. L., & Hu‐Lieskovan, S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280571 · Cited by 74

Tumor Infiltrating Effector Memory Antigen-Specific CD8+ T Cells Predict Response to Immune Checkpoint Therapy

Principe, N., Kidman, J., Goh, S., Tilsed, C. M., Fisher, S. A., Fear, V. S., Forbes, C. A., Zemek, R. M., Chopra, A., Watson, M. W., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584423 · Cited by 76

Multi‐omics analysis of disulfidptosis regulators and therapeutic potential reveals glycogen synthase 1 as a disulfidptosis triggering target for triple‐negative breast cancer

Xie, J., Deng, X., Xie, Y., Zhu, H., Liu, P., Deng, W., Ning, L., Tang, Y., Sun, Y., Tang, H., et al. (2024) · MedComm · doi:10.1002/mco2.502 · Cited by 75

Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers

Peng, D. H., Rodriguez, B. L., Diao, L., Gaudreau, P.-O., Padhye, A., Konen, J. M., Ochieng, J. K., Class, C. A., Fradette, J. J., Gibson, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22875-w · Cited by 72

Dietary elaidic acid boosts tumoral antigen presentation and cancer immunity via ACSL5

Lai, Y., Gao, Y., Lin, J., Liu, F., Yang, L., Zhou, J. H. S., Xue, Y., Li, Y., Chang, Z., Li, J., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.01.012 · Cited by 76

Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy

Schetters, S. T. T., Rodríguez, E., Kruijssen, L. J. W., Crommentuijn, M. H. W., Boon, L., den Bossche, J. V., den Haan, J. M. M., & van Kooyk, Y. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000588 · Cited by 79

Immune infiltration profiling in gastric cancer and their clinical implications

Ren, F., Zhao, Q., Zhao, M., Shaogong, Z., Liu, B., Bukhari, I., Zhang, K., Wu, W., Fu, Y., Yu, Y., et al. (2021) · Cancer Science · doi:10.1111/cas.15057 · Cited by 73

Computational immunogenomic approaches to predict response to cancer immunotherapies

Addala, V., Newell, F., Pearson, J. V., Redwood, A., Robinson, B. W. S., Creaney, J., & Waddell, N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00830-6 · Cited by 79

Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody–Drug Conjugate and Immune Checkpoint Blockade

Boshuizen, J., Pencheva, N., Krijgsman, O., Altimari, D. M. D., Castro, P. G., de Bruijn, B., Ligtenberg, M. A., den Heuvel, E. G.-V., Vredevoogd, D. W., Song, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-0434 · Cited by 73

Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti–PD-1 Therapy

Telli, M. L., Nagata, H., Wapnir, I., Acharya, C. R., Zablotsky, K., Fox, B. A., Bifulco, C. B., Jensen, S. M., Ballesteros‐Merino, C., Le, M. H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3944 · Cited by 72

Soluble PD-L1 as an early marker of progressive disease on nivolumab

Mahoney, K. M., Ross‐Macdonald, P., Yuan, L., Song, L., Veras, E., Wind‐Rotolo, M., McDermott, D. F., Hodi, F. S., Choueiri, T. K., & Freeman, G. J. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003527 · Cited by 72

Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma

Levi, S. T., Copeland, A. R., Nah, S., Crystal, J. S., Ivey, G. D., Lalani, A., Jafferji, M. S., White, B. S., Parikh, N. B., Leko, V., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4499 · Cited by 72

PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade

Srour, N., Villarreal, O. D., Hardikar, S., Yu, Z., Preston, S. E. J., Miller, W. H., Szewczyk, M. M., Baršytė-Lovejoy, D., Xu, H., Chen, T., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110582 · Cited by 70

An artificial intelligence network‐guided signature for predicting outcome and immunotherapy response in lung adenocarcinoma patients based on 26 machine learning algorithms

Zhang, N., Zhang, H., Liu, Z., Dai, Z., Wu, W., Zhou, R., Li, S., Wang, Z., Liang, X., Wen, J., et al. (2023) · Cell Proliferation · doi:10.1111/cpr.13409 · Cited by 71

The liver microenvironment orchestrates FGL1-mediated immune escape and progression of metastatic colorectal cancer

Li, J.-J., Wang, J.-H., Tian, T., Liu, J., Zheng, Y., Mo, H., Sheng, H., Chen, Y., Wu, Q., Han, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42332-0 · Cited by 73

Role of DNA repair defects in predicting immunotherapy response

Zhang, J., Shih, D. J. H., & Lin, S. (2020) · Biomarker Research · doi:10.1186/s40364-020-00202-7 · Cited by 70

Single-cell N6-methyladenosine regulator patterns guide intercellular communication of tumor microenvironment that contribute to colorectal cancer progression and immunotherapy

Gao, Y., Wang, H., Chen, S., An, R., Chu, Y., Li, G., Wang, Y., Xie, X., & Zhang, J. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03395-7 · Cited by 71

CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas

Niborski, L. L., Gueguen, P., Ye, M., Thiolat, A., Ramos, R. N., Caudana, P., Denizeau, J., Colombeau, L., Rodriguez, R., Goudot, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31504-z · Cited by 70

Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies

Pulanco, M. C., Madsen, A. T., Tanwar, A., Corrigan, D. T., & Zang, X. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01019-8 · Cited by 69

Increased diversity with reduced “diversity evenness” of tumor infiltrating T-cells for the successful cancer immunotherapy

Hosoi, A., Takeda, K., Nagaoka, K., Iino, T., Matsushita, H., Ueha, S., Aoki, S., Matsushima, K., Kubo, M., Morikawa, T., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-19548-y · Cited by 69

Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy

Zemek, R. M., Chin, W. L., Nowak, A. K., Millward, M., Lake, R., & Lesterhuis, W. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00223 · Cited by 73

A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response

Hakimi, A. A., Attalla, K., DiNatale, R. G., Ostrovnaya, I., Flynn, J. R., Blum, K. A., Ged, Y. M. A., Hoen, D. R., Kendall, S. M., Reznik, E., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17965-0 · Cited by 68

MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It

Shklovskaya, E., & Rizos, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136741 · Cited by 71

A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype

Chen, Z., Wang, M., Wilde, R. L. D., Feng, R., Su, M., la Roche, L. A. T.-D., & Shi, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.749459 · Cited by 70

Abstract 2988: Immunogenomic analyses of tumor cells and microenvironment in patients with advanced melanoma before and after treatment with nivolumab

Chan, T. A.-T., Riaz, N., Havel, J. J., Makarov, V., Desrichard, A., Sims, J. S., Hodi, F. S., Martín‐Algarra, S., Sharfman, W. H., Bhatia, S., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-2988

Abstract 1125: Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab

Alban, T. J., Riaz, N., Parthasarathy, P. B., Makarov, V., Kendall, S., Yoo, S., Shah, R., Weinhold, N., Srivastava, R. M., Ma, X., et al. (2023) · Cancer Research · doi:10.1158/1538-7445.am2023-1125 · Cited by 1

Tumor control

Visan, I. (2017) · Nature Immunology · doi:10.1038/ni.3878

Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma

Yusko, E. C., Vignali, M., Wilson, R. K., Mardis, E. R., Hodi, F. S., Horak, C. E., Chang, H., Woods, D. M., Robins, H. S., & Weber, J. S. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0226 · Cited by 59

Editors' Picks

(2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.11.011